Dr. Susan Monarez Tapped for CDC Leadership

Dr. Susan Monarez Tapped for CDC Leadership \ Newslooks \ Washington DC \ Mary Sidiqi \ Evening Edition \ President Donald Trump will nominate Dr. Susan Monarez as CDC director. Monarez has been acting CDC chief since January after coming from ARPA-H. Her nomination follows the withdrawal of David Weldon, lacking Senate support due to anti-vaccine ties.

Susan Monarez CDC Nomination Quick Looks:

• President Trump will nominate Dr. Susan Monarez as CDC director.
• Monarez has been serving as acting CDC head since January.
• She previously worked with the Advanced Research Projects Agency for Health (ARPA-H).
• The nomination follows Trump withdrawing David Weldon’s candidacy.
• Weldon, a former congressman, cited insufficient Senate votes for confirmation.
• Weldon was aligned with anti-vaccine advocate Robert F. Kennedy Jr.
• The CDC, headquartered in Atlanta, has a $9.2 billion budget.
• Originally created to fight malaria, CDC now leads on global health.
• Monarez’s background in advanced health research strengthens her candidacy.
• The White House aims to ensure stable CDC leadership amid challenges.

Deep Look

In a significant leadership shift for one of America’s most vital public health agencies, President Donald Trump has announced his intention to nominate Dr. Susan Monarez, currently serving as acting director, to become the permanent director of the U.S. Centers for Disease Control and Prevention (CDC). The White House confirmed the nomination on Monday, signaling a move toward more stability and scientific credibility for the CDC after recent political turbulence and leadership controversies.

Dr. Monarez has been acting CDC director since January 2025, stepping into the role following the abrupt withdrawal of Trump’s initial nominee, former Florida congressman David Weldon. Weldon’s nomination collapsed under mounting Senate opposition, largely due to his close association with U.S. Health Secretary Robert F. Kennedy Jr., a known anti-vaccine activist who has long been at odds with mainstream scientific consensus. Weldon admitted publicly that his nomination was withdrawn because “there were not enough votes to get me confirmed.”

The failed Weldon nomination created urgency within the White House to find a nominee with a stronger scientific pedigree and fewer political liabilities. Enter Dr. Susan Monarez — a highly respected health scientist and administrator who previously held a leadership position at the Advanced Research Projects Agency for Health (ARPA-H). ARPA-H is known for pioneering health research projects and developing rapid-response medical solutions, giving Monarez a solid background in navigating complex public health challenges and innovative research.

The CDC, based in Atlanta, has a $9.2 billion core budget and oversees national and international efforts to monitor, prevent, and respond to public health threats. Originally established nearly eight decades ago to fight malaria outbreaks in the southern United States, the CDC has since evolved into one of the world’s foremost authorities on infectious disease prevention, chronic disease management, environmental health monitoring, and emergency response. The agency is often called upon to guide the nation through health crises, as seen during the COVID-19 pandemic.

Trump’s choice of Monarez is being interpreted by political analysts and public health experts as an attempt to stabilize the CDC and restore scientific credibility to an agency whose reputation has taken a hit in recent years. Monarez’s research-driven background, combined with her lack of overt political affiliations, positions her as a more palatable candidate for Senate confirmation and for restoring morale within the CDC’s workforce.

The withdrawal of Weldon’s nomination was not without controversy. His political alignment with Robert F. Kennedy Jr., who has long been one of the most prominent anti-vaccine figures in the country, sparked immediate backlash from public health advocates, scientific organizations, and members of both parties. Given the CDC’s central role in vaccine development, distribution, and education, Weldon’s potential leadership raised concerns that the agency’s mission could become compromised by political ideology rather than science-based policy.

Monarez’s nomination appears to be a direct response to those concerns. With her extensive experience in advanced medical research and public health policy development at ARPA-H, Monarez is expected to focus on evidence-based strategies, data-driven decision-making, and rebuilding public trust in CDC guidance.

The CDC faces mounting challenges in 2025. In addition to ongoing COVID-19 variant management, the agency is tackling rising cases of influenza, new outbreaks of infectious diseases linked to climate change, growing mental health crises, and the increasing problem of antibiotic resistance. The CDC is also focusing on modernizing its data infrastructure, improving its rapid-response capabilities, and combatting public health misinformation that has eroded confidence in vaccinations and preventative health measures.

Monarez is stepping into a position that requires not just scientific acumen but also political savvy. The CDC has faced criticism for inconsistent messaging during the COVID-19 pandemic, often caught between shifting political pressures and evolving science. Many health officials and lawmakers are hoping that Monarez’s tenure will be marked by more consistent, transparent communication and stronger collaboration with state and international health agencies.

Early signs suggest that Monarez will enjoy bipartisan support. Her reputation for balancing research innovation with practical health solutions has earned praise from both scientific communities and political observers who prioritize effective leadership over political loyalty. Lawmakers on both sides of the aisle are expected to press her on plans to improve CDC transparency, enhance emergency preparedness, and rebuild trust in public health messaging during her upcoming confirmation hearings.

Globally, the CDC continues to play a vital role in disease surveillance, outbreak response, and international health partnerships. Under Monarez’s leadership, the agency is expected to deepen collaborations with the World Health Organization and global health networks, aiming to strengthen early warning systems for emerging diseases and improve vaccine distribution logistics worldwide.

For the Trump administration, this nomination comes at a critical moment, as public health remains a central concern and political issue in the lead-up to the 2026 midterm elections. While Monarez is not a political figure, her leadership could influence public perceptions of the administration’s commitment to science-based health policies.

The next steps for Dr. Monarez include undergoing Senate confirmation hearings, where she will likely be questioned about her strategy for handling future pandemics, restoring CDC independence, and preventing the kind of political interference that marred parts of the agency’s response to COVID-19. Public health leaders have already begun voicing cautious optimism that her background in medical research and health innovation will bring stability and expertise to an agency in need of both.

As the CDC prepares for its next chapter, all eyes will be on Monarez to see if she can navigate the complex intersection of science, public trust, and politics — and ultimately restore the CDC’s standing as the nation’s go-to authority on public health and safety.

More on US News